Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tayyaba I Khan

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Pharmacogenetics and Genomics|July 19, 2006
APOE genotype makes a small contribution to warfarin dose requirementsElizabeth A Sconce, Ann K Daly, Tayyaba I Khan, et al.
Pharmacogenetics|December 21, 2004
Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolismBarry P King, Tayyaba I Khan, Guruprasad P Aithal, et al.
Blood|June 11, 2005
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenElizabeth A Sconce, Tayyaba I Khan, Hilary A Wynne, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Pharmacogenetics and Genomics|July 19, 2006
APOE genotype makes a small contribution to warfarin dose requirementsElizabeth A Sconce, Ann K Daly, Tayyaba I Khan, et al.
Pharmacogenetics|December 21, 2004
Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolismBarry P King, Tayyaba I Khan, Guruprasad P Aithal, et al.
Blood|June 11, 2005
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenElizabeth A Sconce, Tayyaba I Khan, Hilary A Wynne, et al.
Pageof 1